Cancer Novartis’ breast cancer drug LEEO11 gains breakthrough statu... Drug will challenge Pfizer's Ibrance
News Pharma faces pressure whoever wins Presidential race, warns ... Novartis chief warns on US pricing pressure
News Novartis buys into bispecific antibodies with Xencor deal Agreement could add to Novartis' immuno-oncology pipeline.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.